Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Toronto Stock Exchange  >  Oncolytics Biotech Inc.    ONC   CA6823108759

ONCOLYTICS BIOTECH INC. (ONC)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Toronto Stock Exchange
07/16/2018 07/17/2018 07/18/2018 07/19/2018 07/20/2018 Date
7.1(c) 7.12(c) 6.9(c) 7.07(c) 6.99 Last
5 114 9 000 11 138 4 326 200 Volume
0.00% +0.28% -3.09% +2.46% -1.13% Change
More quotes
Financials (CAD)
Sales 2018 4,33 M
EBIT 2018 -13,3 M
Net income 2018 -12,2 M
Debt 2018 -
Yield 2018 -
Sales 2019 5,00 M
EBIT 2019 -
Net income 2019 -20,8 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 27,3x
Capi. / Sales2019 23,6x
Capitalization 118 M
More Financials
Company
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies.It offers a non-pathogenic, properietary isolate of the reovirus called REOLYSIN.The company was founded by Matthew C. Coffey and Bradley George Thompson on... 
More about the company
Latest news on ONCOLYTICS BIOTECH INC.
07/18Today's Free Reports Concordia International ProMetic Life Sciences Oncolytic..
AC
07/11Today's Research Reports on Emblem, OrganiGram, Oncolytics Biotech and Aptose..
AC
06/20Today's Free Reports Concordia International, ProMetic Life Sciences, Aurinia..
AC
06/05Oncolytics Biotech® Closes USD $8.9 Million Public Offering of Common Shares
GL
06/04ONCOLYTICS BIOTECH : reg; Announces Poster Presentation Demonstrating the Abilit..
PU
06/01ONCOLYTICS BIOTECH : Announces Public Offering of Common Shares
AQ
05/31Oncolytics Biotech® Announces Public Offering of Common Shares
GL
More news
Sector news : Biotechnology & Medical Research - NEC
07/19Novartis, MorphoSys and Galapagos Shares Rise on News of Deal
DJ
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
06/28Oncolytics Biotech $ONCY Lowered to Hold at ValuEngine  
06/06Oncolytics Biotech® Closes USD $8.9 Million Public Offering of Common Shares .. 
06/01Oncolytics Biotech® Prices USD $8,000,000 Million Public Offering of Common S.. 
06/01Oncolytics Biotech® Prices USD $8,000,000 Million Public Offering of Common S.. 
06/01Oncolytics Biotech® Announces Listing on Nasdaq Capital Market  
More tweets
Qtime:11
News from SeekingAlpha
07/11ONCOLYTICS : Significant Pipeline Value In The Fastest Growing Area Of Oncology. 
07/01WEEK IN REVIEW : CStone Acquires China Rights To Leukemia Drug In $424 Million D.. 
06/11FUTURE DIRECTIONS FOR ONCOLYTICS :   Partnerships + Buyouts 
Chart ONCOLYTICS BIOTECH INC.
Duration : Period :
Oncolytics Biotech Inc. Technical Analysis Chart | ONC | CA6823108759 | 4-Traders
Technical analysis trends ONCOLYTICS BIOTECH INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 22,2  CAD
Spread / Average Target 221%
EPS Revisions
Managers
NameTitle
Matthew C. Coffey President, CEO, COO & Director
Wayne F. Pisano Chairman
Kirk J. Look Chief Financial Officer
J. Mark Lievonen Independent Director
Angela Holtham Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ONCOLYTICS BIOTECH INC.2.30%89
CELLTRION, INC.--.--%32 830
IQVIA HOLDINGS INC12.03%22 488
LONZA GROUP9.31%21 400
INCYTE CORPORATION-25.70%14 887
SEATTLE GENETICS, INC.27.16%10 750